Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Unternehmen & Branche
| Name | Ocugen, Inc. |
|---|---|
| Ticker | OCGN |
| CIK | 0001372299 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 550,9 Mio. USD |
| Beta | 2,81 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 4,413,000 | -67,846,000 | 43,516,000 | -12,166,000 | |
| 2025-09-30 | 10-Q | 1,752,000 | -20,051,000 | 57,596,000 | 3,533,000 | |
| 2025-06-30 | 10-Q | 1,373,000 | -14,739,000 | 53,594,000 | 3,052,000 | |
| 2025-03-31 | 10-Q | 1,481,000 | -15,350,000 | 64,460,000 | 15,914,000 | |
| 2024-12-31 | 10-K | 4,055,000 | -54,054,000 | 82,442,000 | 29,632,000 | |
| 2024-09-30 | 10-Q | 1,136,000 | -12,970,000 | 61,936,000 | 40,630,000 | |
| 2024-06-30 | 10-K | -15,280,000 | ||||
| 2024-06-30 | 10-Q | 1,141,000 | -15,280,000 | -0.04 | 40,542,000 | 16,927,000 |
| 2024-03-31 | 10-K | -11,924,000 | ||||
| 2024-03-31 | 10-Q | 1,014,000 | -11,924,000 | -0.05 | 51,794,000 | 30,261,000 |
| 2023-12-31 | 10-K | 6,036,000 | -63,078,000 | -0.26 | 64,547,000 | 40,564,000 |
| 2023-09-30 | 10-K | 3,699,000 | -11,717,000 | -0.05 | 74,687,000 | 49,801,000 |
| 2023-09-30 | 10-Q | 3,699,000 | -11,717,000 | -0.06 | 74,687,000 | 49,801,000 |
| 2023-06-30 | 10-K | 485,000 | -23,065,000 | -0.10 | 88,976,000 | 59,242,000 |
| 2023-06-30 | 10-Q | 485,000 | -23,065,000 | -0.10 | 88,976,000 | 59,242,000 |
| 2023-03-31 | 10-Q | 443,000 | -17,326,000 | -0.08 | 96,299,000 | 64,901,000 |
| 2023-03-31 | 10-K | 443,000 | -17,326,000 | -0.08 | 96,299,000 | 64,901,000 |
| 2022-12-31 | 10-K | 2,488,000 | -86,804,000 | -0.40 | 108,632,000 | 73,981,000 |
| 2022-09-30 | 10-Q | -21,922,000 | -0.10 | 116,239,000 | 95,303,000 | |
| 2022-09-30 | 10-K | 466,000 | -23,913,000 | -0.11 | 116,239,000 | 85,687,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.